Royalty Pharma CEO granted 143,821 RPRX shares
Royalty Pharma plc director and CEO Pablo G. Legorreta received 143,821 Class A Ordinary Shares as an equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Royalty Pharma plc director and CEO Pablo G. Legorreta received 143,821 Class A Ordinary Shares as an equity award. The shares were granted at $0.00 per share in connection with the settlement of Equity Performance Awards and are described as an exempt acquisition under Rule 16b-3. Following this grant, Legorreta directly holds 1,240,604 Class A Ordinary Shares. He also has indirect holdings through family members and related entities, including 1,040,410 shares held by the Legorreta Children 2002 Trust and 901,590 shares held by the GST-Exempt Legorreta 2012 Family Trust. The filing does not show any open-market purchases or sales, indicating a routine compensation-related share award rather than a discretionary trade.
Insider Trade Summary
Grant/Award: 143,821 shares
Grant/Award
12 txns
Insider
Legorreta Pablo G.
Role
CEO, Chairman of the Board
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Ordinary Shares | 143,821 | $0.00 | $0.00 |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Class A Ordinary Shares — 1,242,604 shares (Direct);
Class A Ordinary Shares — 1,040,410 shares (Indirect, By Legorreta Children 2002 Trust);
Class A Ordinary Shares — 901,590 shares (Indirect, By GST-Exempt Legorreta 2012 Family Trust);
Class A Ordinary Shares — 600,000 shares (Indirect, By Legorreta 2023 SR Trust);
Class A Ordinary Shares — 460,139 shares (Indirect, By Legorreta Investments LLC);
Class A Ordinary Shares — 292,190 shares (Indirect, By Tata MC 35 Ltd.);
Class A Ordinary Shares — 123,310 shares (Indirect, By IRRA);
Class A Ordinary Shares — 118,500 shares (Indirect, By SEP/IRA);
Class A Ordinary Shares — 41,306 shares (Indirect, By GST-Exempt Legorreta 2020 Family Trust);
Class A Ordinary Shares — 10,000 shares (Indirect, By Son);
Class A Ordinary Shares — 10,000 shares (Indirect, By Daughter);
Class A Ordinary Shares — 6,930 shares (Indirect, By Spouse)
Footnotes (1)
- F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
Key Figures
Equity award shares: 143,821 shares
Award price per share: $0.00 per share
Direct holdings after award: 1,240,604 shares
+2 more
5 metrics
Equity award shares
143,821 shares
Class A Ordinary Shares granted as Equity Performance Awards settlement
Award price per share
$0.00 per share
Grant price for 143,821 Class A Ordinary Shares
Direct holdings after award
1,240,604 shares
Class A Ordinary Shares directly held by Pablo G. Legorreta after transaction
Legorreta Children 2002 Trust holdings
1,040,410 shares
Class A Ordinary Shares held indirectly via Legorreta Children 2002 Trust
GST-Exempt 2012 Family Trust holdings
901,590 shares
Class A Ordinary Shares held indirectly via GST-Exempt Legorreta 2012 Family Trust
Key Terms
Class A Ordinary Shares, Rule 16b-3, Equity Performance Awards, indirect ownership
4 terms
Rule 16b-3 regulatory
"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Equity Performance Awards financial
"Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards"
indirect ownership financial
"Entries list Class A Ordinary Shares held indirectly by spouse, children, trusts, and entities"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Royalty Pharma (RPRX) CEO Pablo G. Legorreta report on this Form 4?
Pablo G. Legorreta reported receiving 143,821 Class A Ordinary Shares as an equity award. The grant relates to settlement of Equity Performance Awards and is classified as an exempt acquisition under Rule 16b-3, rather than an open-market transaction or discretionary trade.
Were there any open-market buys or sells in this Royalty Pharma (RPRX) Form 4?
The Form 4 does not show any open-market purchases or sales. It mainly records an exempt acquisition of 143,821 Class A Ordinary Shares as an equity performance-based award, along with multiple indirect holdings through family members, trusts, and related investment entities.
What does the Rule 16b-3 exempt acquisition mean for Royalty Pharma (RPRX) CEO’s award?
The filing states the award is an exempt acquisition under Rule 16b-3, tied to settling Equity Performance Awards. This means the 143,821-share grant is a compensation-related transaction approved under specific SEC rules, not a typical market trade initiated by the CEO.
What indirect Royalty Pharma (RPRX) holdings are associated with Pablo G. Legorreta?
Indirect holdings include shares held by his spouse, children, retirement accounts, and several trusts and entities. Examples are 1,040,410 shares held by the Legorreta Children 2002 Trust and 901,590 shares held by the GST-Exempt Legorreta 2012 Family Trust, as disclosed in the filing.
Does this Royalty Pharma (RPRX) Form 4 suggest a change in insider sentiment?
The Form 4 reflects a compensation-related equity grant rather than market buying or selling. Since the 143,821-share award is tied to Equity Performance Awards and exempt under Rule 16b-3, it primarily updates ownership records without signaling a discretionary change in insider sentiment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
